X0306 4 2019-10-16 0 0001706431 Vir Biotechnology, Inc. VIR 0001782338 SVF Endurance (Cayman) Ltd C/O WALKERS CORP LTD CAYMAN CORP CENTRE 27 HOSPITAL ROAD GEORGETOWN, GRAND CAYMAN E9 KY1-9008 CAYMAN ISLANDS 0 0 1 0 0001731509 SB INVESTMENT ADVISERS (UK) LTD 69 GROSVENOR STREET LONDON X0 W1K 3JW UNITED KINGDOM 0 0 1 0 0001755143 SOFTBANK VISION FUND (AIV M1) L.P. 251 LITTLE FALLS DRIVE WILMINGTON DE 19808 0 0 1 0 Common Stock, par value $0.0001 per share 2019-10-16 4 C 0 21666666 A 21666666 I See footnote Common Stock, par value $0.0001 per share 2019-10-16 4 P 0 950000 20.00 A 22616666 I See footnote Series A-1 Convertible Preferred Stock 2019-10-16 4 C 0 15555555 0.00 D Common Stock 15555555 0 I See footnote Series B Convertible Preferred Stock 2019-10-16 4 C 0 6111111 0.00 D Common Stock 6111111 0 I See footnote The Series A-1 Convertible Preferred Stock and the Series B Convertible Preferred Stock each converted into Vir Biotechnology, Inc. common stock on a one-to-one basis and had no expiration date. Represents securities held directly by SVF Endurance (Cayman) Limited. SVF Endurance (Cayman) Limited is a wholly-owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. (continued from footnote 2) SBIA UK is wholly owned by SoftBank Group Corp. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission that any reporting person is the beneficial owner of such shares for purposes of the Securities Exchange Act of 1934 or for any other purpose. /s/ Karen Ellerbe, Director of SVF Endurance (Cayman) Limited 2019-10-16 /s/ Brian Wheeler, General Counsel of SB Investment Advisers (UK) Limited, manager of SoftBank Vision Fund (AIV M1) L.P. 2019-10-16 /s/ Brian Wheeler, General Counsel of SB Investment Advisers (UK) Limited 2019-10-16